In high-risk patients with pulmonary arterial hypertension, Merck ’s fusion protein therapeutic Winrevair reduced the ...

Merck & Co said on Thursday that it plans to launch a subcutaneously injected version of its blockbuster cancer immunotherapy ...

Healthcare pioneer Laura Shawver, Ph.D. appointed Chair of the Board and industry veteran Roy Baynes M.D., Ph.D. appointed as independent, non-exe ...

February saw several changes on boards at biotechs, bringing a diverse wealth of experience to support these companies. Read ...

PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies ...

Vizgen, Inc., the life sciences company revolutionizing spatial genomics research and driving innovation in spatial ...

Summary: The Board erred by failing to explain why it discarded material and unrebutted evidence that a reference constitutes prior art.

The general mood among these heavyweight investors is divided, with 63% leaning bullish and 36% bearish. Among these notable options, 6 are puts, totaling $487,682, and 5 are calls, amounting to ...

Discover the latest April 2025 update on Dow Dogs! Learn about top investment picks, forecasted gains, and market corrections ...

The California-based company is trying to get Merck on board with a licensing arrangement, but it’s prepared to resort to lawsuits if that attempt fails, Halozyme CEO Helen Torley said Wednesday ...

Recursion Pharmaceuticals appointed former FDA principal deputy commissioner Namandjé Bumpus, PhD, and Elaine Sun, the COO and CFO of Mammoth Biosciences, to its board of directors. CAMP4 Therapeutics ...